Top

BMC Cancer

Published in:

Open Access 01-12-2019 | Metastasis | Research article

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

Authors: Mark T. J. van Bussel, Jos H. Beijnen, Dieta Brandsma

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases. However, it is generally assumed that large molecules like monoclonal antibodies nivolumab and ipilimumab cannot penetrate and pass an intact blood brain barrier (BBB). In this systematic review we provide a pharmacodynamic and pharmacokinetic consideration of the clinical activity of the immune checkpoint inhibitors nivolumab and ipilimumab in melanoma brain metastases.

Methods

Pubmed was systematically searched for prospective phase II and III studies on nivolumab and ipilimumab in melanoma brain metastases and cerebrospinal fluid (CSF) levels of nivolumab and ipilimumab. Results were discussed and a perspective on the pharmacodynamics and pharmacokinetics for the intracranial activity of these agents was given.

Results

Two phase II studies with the combination nivolumab and ipilimumab and one phase II study with ipilimumab monotherapy in melanoma brain metastases were included in this review. One article reported drug levels of nivolumab in CSF. Intracranial responses were achieved in 16 of 35 patients (46%; 95% confidence interval (CI) 29–63) in a phase II study cohort treated with nivolumab and ipilimumab. In a second phase II study in 94 patients, the rate of intracranial clinical benefit was 57% (95% CI 47–68). The CSF/serum ratio of nivolumab was 0.88–1.9% in a cohort of metastatic melanoma patients treated with nivolumab 1–3 mg/kg. Nivolumab concentrations ranged from 35 to 150 ng/ml in CSF of these patients, which is in the range of the half maximal effective concentration (EC50) of 0.64 nM.

Conclusions

Ipilimumab and nivolumab are active in melanoma brain metastases. Nivolumab penetrates into the CSF. Based on the described findings the general consensus that monoclonal antibodies do not penetrate into the central nervous system (CNS) and cannot have a direct intracranial effect needs to be reconsidered.

Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. ESMO guidelines committee. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2015;26(Suppl 5):v126–32. https://doi.org/10.1093/annonc/mdv297. CrossRef

European Medicines Agency. Summary of product characteristics Nivolumab. Available at https://www.ema.europa.eu/en. Accessed 12 Sept 2018.

Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology. 2015;66:289–99. https://doi.org/10.1111/his.12537.CrossRefPubMed

Morales-Betanzos CA, Lee H, Gonzalez Ericsson PI, Balko JM, Johnson DB, Zimmerman LJ, et al. Quantitative mass spectrometry analysis of PD-L1 protein expression, N -glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Mol Cell Proteomics. 2017;16:1705–17. https://doi.org/10.1074/mcp.RA117.000037.CrossRefPubMedPubMedCentral

Summary of product characteristics Ipilimumab. Available at https://www.ema.europa.eu/en. Accessed 14 Sept 2018.

Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–8.CrossRef

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. https://doi.org/10.1056/NEJMoa1504030.CrossRefPubMedPubMedCentral

Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, et al. Barriers to effective drug treatment for brain metastases: a multifactorial problem in the delivery of precision medicine. Pharm Res. 2018;35:177. https://doi.org/10.1007/s11095-018-2455-9.CrossRefPubMed

Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not)? Trends Immunol. 2007;28:5–11.CrossRef

10.

Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQM. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro-Oncology. 2017;19:i1–24. https://doi.org/10.1093/neuonc/now197.CrossRefPubMed

11.

Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem. 1980;23:682–4. https://doi.org/10.1021/jm00180a022.CrossRefPubMed

12.

Pardridge WM. Delivery of biologics across the blood-brain barrier with molecular Trojan horse technology. BioDrugs. 2017;31:503–19. https://doi.org/10.1007/s40259-017-0248-z.CrossRefPubMed

13.

Zhao YH, Abraham MH, Ibrahim A, Fish PV, Cole S, Lewis ML, et al. Predicting penetration across the blood-brain barrier from simple descriptors and fragmentation schemes. J Chem Inf Model. 2007;47:170–5. https://doi.org/10.1021/ci600312d.CrossRefPubMed

14.

Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF. Drug delivery to melanoma brain metastases: can current challenges lead to new opportunities? Pharmacol Res. 2017;123:10–25. https://doi.org/10.1016/j.phrs.2017.06.008.CrossRefPubMedPubMedCentral

15.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722–30. https://doi.org/10.1056/NEJMoa1805453.CrossRefPubMed

16.

Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672–81. https://doi.org/10.1016/S1470-2045(18)30139-6.CrossRefPubMed

17.

Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12:623–35. https://doi.org/10.1038/nri3265.CrossRefPubMed

18.

Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337–41. https://doi.org/10.1038/nature14432.CrossRefPubMedPubMedCentral

19.

Louveau A, Herz J, Alme MN, Salvador AF, Dong MQ, Viar KE, et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat Neurosci. 2018;21:1380–91. https://doi.org/10.1038/s41593-018-0227-9.CrossRefPubMedPubMedCentral

20.

Amit M, Laider-Trejo L, Shalom V, Shabtay-Orbach A, Krelin Y, Gil Z. Characterization of the melanoma brain metastatic niche in mice and humans. Cancer Med. 2013;2:155–63. https://doi.org/10.1002/cam4.45.CrossRefPubMedPubMedCentral

21.

Berghoff AS, Lassmann H, Preusser M, Höftberger R. Characterization of the inflammatory response to solid cancer metastases in the human brain. Clin Exp Metastasis. 2013;30:69–81. https://doi.org/10.1007/s10585-012-9510-4.CrossRefPubMed

22.

Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459–65. https://doi.org/10.1016/S1470-2045(12)70090-6.CrossRefPubMed

23.

https://clinicaltrials.gov/ct2/results?term=nivolumab+ipilimumab&type=Intr&cond=melanoma+brain+metastases&rank=4#rowId3. Accessed 2 Jan 2019.

24.

Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009;39:469–77. https://doi.org/10.1111/j.1365-2222.2009.03207.x.CrossRefPubMed

25.

van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange. Science. 2007;317:1554–7. https://doi.org/10.1126/science.1144603.CrossRefPubMed

26.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75. https://doi.org/10.1200/JCO.2009.26.7609.CrossRefPubMedPubMedCentral

27.

Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs. 2010;2:233–55. https://doi.org/10.4161/mabs.2.3.11782.CrossRefPubMedPubMedCentral

28.

Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys. 2012;526:159–66. https://doi.org/10.1016/j.abb.2012.03.021.CrossRefPubMed

29.

Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22:1212–21. https://doi.org/10.1634/theoncologist.2017-0167.CrossRefPubMedPubMedCentral

30.

Sancho-Lopez A, de Graeff P, European Medicines Agency, Assessment report nivolumab EMA/CHMP/76688/2015. https://www.ema.europa.eu/en/documents/assessment-report/opdivo-epar-public-assessment-report_en.pdf. Accessed 14 Sept 2018.

31.

Food and Drug Administration. Prescribing information nivolumab. 2015.

32.

Pluim D, Ros W, van Bussel MTJ, Brandsma D, Beijnen JH, Schellens JHM. Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. J Pharm Biomed Anal. 2018;164:128–34. https://doi.org/10.1016/j.jpba.2018.10.025.CrossRefPubMed

33.

van Zwieten-Boot B, Sancho-Lopez EMA. Assessment report ipilimumab EMA/CHMP/557664/. 2011.

34.

Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds PJ, et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol. 1993;151:3489–99.PubMed

35.

Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–64. https://doi.org/10.1016/S1470-2045(09)70334-1.CrossRefPubMed

36.

Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950–6. https://doi.org/10.1200/JCO.2008.16.1927.CrossRefPubMed

37.

Department of Health and Ageing Australian Government. Australian public assessment report for Ipilimumab. 2011.

38.

Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–58. https://doi.org/10.1038/clpt.2008.170.CrossRefPubMed

39.

Medesan C, Radu C, Kim JK, Ghetie V, Ward ES. Localization of the site of the IgG molecule that regulates maternofetal transmission in mice. Eur J Immunol. 1996;26:2533–6. https://doi.org/10.1002/eji.1830261038.CrossRefPubMed

40.

Brazil MI, Chung H, Maxfield FR. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer’s disease amyloid fibrils by microglia. J Biol Chem. 2000;275:16941–7. https://doi.org/10.1074/jbc.M000937200.CrossRefPubMed

41.

Benarroch EE. Choroid plexus--CSF system: recent developments and clinical correlations. Neurology. 2016;86:286–96. https://doi.org/10.1212/WNL.0000000000002298.CrossRefPubMed

42.

Hulse RE, Swenson WG, Kunkler PE, White DM, Kraig RP. Monomeric IgG is neuroprotective via enhancing microglial recycling endocytosis and TNF-alpha. J Neurosci. 2008;28:12199–211. https://doi.org/10.1523/JNEUROSCI.3856-08.2008.CrossRefPubMedPubMedCentral

43.

Scott-Taylor TH, Axinia S-C, Amin S, Pettengell R. Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy. Immunity Inflamm Dis. 2018;6:13–33. https://doi.org/10.1002/iid3.192.CrossRef

Title: Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review
Authors: Mark T. J. van Bussel
Jos H. Beijnen
Dieta Brandsma
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Metastasis
Melanoma
Melanoma
Pharmacodynamics
Pharmacokinetics
Checkpoint Inhibitors
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-5741-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Androgen receptor and FOXA1 coexpression define a “luminal-AR” subtype of feline mammary carcinomas, spontaneous models of breast cancer

Identification of differentially expressed lncRNAs and mRNAs in luminal-B breast cancer by RNA-sequencing

Paracrine effects of CCN3 from non-cancerous hepatic cells increase signaling and progression of hepatocellular carcinoma

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer

Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer